230 related articles for article (PubMed ID: 17447435)
1. Green tea catechins as brain-permeable, non toxic iron chelators to "iron out iron" from the brain.
Mandel S; Weinreb O; Reznichenko L; Kalfon L; Amit T
J Neural Transm Suppl; 2006; (71):249-57. PubMed ID: 17447435
[TBL] [Abstract][Full Text] [Related]
2. Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders.
Mandel S; Amit T; Reznichenko L; Weinreb O; Youdim MB
Mol Nutr Food Res; 2006 Feb; 50(2):229-34. PubMed ID: 16470637
[TBL] [Abstract][Full Text] [Related]
3. Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.
Mandel S; Maor G; Youdim MB
J Mol Neurosci; 2004; 24(3):401-16. PubMed ID: 15655262
[TBL] [Abstract][Full Text] [Related]
4. Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway.
Mandel SA; Avramovich-Tirosh Y; Reznichenko L; Zheng H; Weinreb O; Amit T; Youdim MB
Neurosignals; 2005; 14(1-2):46-60. PubMed ID: 15956814
[TBL] [Abstract][Full Text] [Related]
5. Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3-gallate: implications for neurodegenerative diseases.
Mandel S; Weinreb O; Amit T; Youdim MB
J Neurochem; 2004 Mar; 88(6):1555-69. PubMed ID: 15009657
[TBL] [Abstract][Full Text] [Related]
6. Neurodegenerative diseases and therapeutic strategies using iron chelators.
Ward RJ; Dexter DT; Crichton RR
J Trace Elem Med Biol; 2015; 31():267-73. PubMed ID: 25716300
[TBL] [Abstract][Full Text] [Related]
7. Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG.
Avramovich-Tirosh Y; Reznichenko L; Mit T; Zheng H; Fridkin M; Weinreb O; Mandel S; Youdim MB
Curr Alzheimer Res; 2007 Sep; 4(4):403-11. PubMed ID: 17908043
[TBL] [Abstract][Full Text] [Related]
8. Green Tea Catechins Attenuate Neurodegenerative Diseases and Cognitive Deficits.
Afzal O; Dalhat MH; Altamimi ASA; Rasool R; Alzarea SI; Almalki WH; Murtaza BN; Iftikhar S; Nadeem S; Nadeem MS; Kazmi I
Molecules; 2022 Nov; 27(21):. PubMed ID: 36364431
[TBL] [Abstract][Full Text] [Related]
9. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Youdim MB; Stephenson G; Ben Shachar D
Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
[TBL] [Abstract][Full Text] [Related]
10. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases.
Weinreb O; Mandel S; Amit T; Youdim MB
J Nutr Biochem; 2004 Sep; 15(9):506-16. PubMed ID: 15350981
[TBL] [Abstract][Full Text] [Related]
11. Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease.
Reznichenko L; Amit T; Zheng H; Avramovich-Tirosh Y; Youdim MB; Weinreb O; Mandel S
J Neurochem; 2006 Apr; 97(2):527-36. PubMed ID: 16539659
[TBL] [Abstract][Full Text] [Related]
12. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
[TBL] [Abstract][Full Text] [Related]
13. Epigallocatechin-3-gallate and epicatechin-3-gallate from green tea decrease plasma non-transferrin bound iron and erythrocyte oxidative stress.
Thephinlap C; Ounjaijean S; Khansuwan U; Fucharoen S; Porter JB; Srichairatanakool S
Med Chem; 2007 May; 3(3):289-96. PubMed ID: 17504202
[TBL] [Abstract][Full Text] [Related]
14. Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases.
Gonçalves PB; Sodero ACR; Cordeiro Y
Biomolecules; 2021 May; 11(5):. PubMed ID: 34065606
[TBL] [Abstract][Full Text] [Related]
15. Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents.
Mandel S; Amit T; Bar-Am O; Youdim MB
Prog Neurobiol; 2007 Aug; 82(6):348-60. PubMed ID: 17659826
[TBL] [Abstract][Full Text] [Related]
16. The potential application of iron chelators for the treatment of neurodegenerative diseases.
Hider RC; Roy S; Ma YM; Le Kong X; Preston J
Metallomics; 2011 Mar; 3(3):239-49. PubMed ID: 21344071
[TBL] [Abstract][Full Text] [Related]
17. Iron: a new target for pharmacological intervention in neurodegenerative diseases.
Whitnall M; Richardson DR
Semin Pediatr Neurol; 2006 Sep; 13(3):186-97. PubMed ID: 17101458
[TBL] [Abstract][Full Text] [Related]
18. Novel therapeutic approach for neurodegenerative pathologies: multitarget iron-chelating drugs regulating hypoxia-inducible factor 1 signal transduction pathway.
Weinreb O; Amit T; Mandel S; Youdim MB
Neurodegener Dis; 2012; 10(1-4):112-5. PubMed ID: 22156453
[TBL] [Abstract][Full Text] [Related]
19. Catechins as Tools to Understand the Molecular Basis of Neurodegeneration.
Martinez Pomier K; Ahmed R; Melacini G
Molecules; 2020 Aug; 25(16):. PubMed ID: 32781559
[TBL] [Abstract][Full Text] [Related]
20. Oxidative stress and neurodegeneration: the involvement of iron.
Carocci A; Catalano A; Sinicropi MS; Genchi G
Biometals; 2018 Oct; 31(5):715-735. PubMed ID: 30014355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
